May 15, 2024
1 min watch
Save
VIDEO: Gene therapy-associated uveitis must be mitigated to improve clinical trials
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, David Almeida, MD, MBA, PhD, discusses combating gene therapy-associated uveitis.
According to Almeida, gene therapy associated-uveitis may cause severe inflammation in patients, which limits their ability to participate in clinical trials.
“I think as more and more gene therapy platforms become potential platforms for a mainstay of treatment, these will be the critical things we need to mitigate to avoid adverse events,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Almeida D. Gene therapy-associated uveitis. Presented at: Retina World Congress; May 9-12, 2024; Fort Lauderdale, Florida.
Disclosures:
Almeida reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.